Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031642 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00031642 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 26 participants.
The verdict
NCT00031642, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Radiolabeled monoclonal antibodies can locate and deliver radioactive cancer-killing substances. PURPOSE: Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibodies with rituximab in treating patients who have non-Hodgkin's lymphoma that has not responded to high-dose chemotherapy and autologous stem cell transplantation.
Interventions
- BIOLOGICAL rituximab
- RADIATION yttrium Y 90 ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2002-01-01 |
| Est. Completion | 2008-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031642
The ClinicalTrials.gov registry entry for NCT00031642 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00031642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031642 about?
NCT00031642 is a clinical study titled "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation". RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Radiolabeled monoclonal antibodies can locate and deliver radioactive cancer-killing substances. PURPOSE: Phase I/II trial to study the effectivenes...
What is the current status of trial NCT00031642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2002-01-01. Estimated completion is 2008-03-01.
What interventions are being tested in trial NCT00031642?
The interventions under investigation include: rituximab (BIOLOGICAL), yttrium Y 90 ibritumomab tiuxetan (RADIATION).
Who is sponsoring clinical trial NCT00031642?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.